Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult diabetics in Finland. Results from large national database between 2000 and 2006

Journal of Hypertension

Volumn 27, Issue 11, 2009, Pages 2283-2293

  Ahola, Teemu L ^a   Jula, Antti M ^a   Kantolab, Ilkka M ^b   Mäki, Juhani ^a   Klaukka, Timo ^c   Reunanen, Antti ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

Blood pressure; Diabetes; Drug therapy; Dyslipidemia; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BEHAVIOR CHANGE; BLOOD PRESSURE REGULATION; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; FINLAND; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREND STUDY;

EID: 73249146023     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328330b6bf     Document Type: Article

References (44)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462-1536.
2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. SMJ 1998; 317:703-713.
3. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
4. McAlister FA, Campbell NR, Duong-Hua M, Chen Z, Tu K. Antihypertensive medication prescribing in 27 822 elderly Canadians with diabetes over the past decade. Diabetes Care 2006; 29:836-841. (Pubitemid 44115303)
5. Gulliford MC, Charlton J, Latinovic R. Trends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion? J Hum Hypertens 2005; 19:111-117. (Pubitemid 40220633)
6. Grant RW, Pirraglia PA, Meigs JB, Singer DE. Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med 2004; 164:1134-1139.
7. Eurich DT, Gamble JM, Simpson SH, Johnson JA. The darkening cloud of diabetes: do trends in cardiovascular risk management provide a silver lining? Diabetes Care 2008; 31:2136-2142.
8. Cheung BM, Ong KL, Man YB, Lam KS, Lau CP. Prevalence, awareness, treatment and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens (Greenwich) 2006; 8:93-98.
9. lmperatore G, Cadwell BL, Geiss L, Saadinne JB, Williams DE, Ford ES, et al. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971 -2000. Am J Epidemiol 2004; 160:531-539.
10. Schiel R, Muller UA, Beltschikow W, Stein G. Trends in the management of arterial hypertension in patients with type 1 and insulin-treated type 2 diabetes mellitus over a period of 10 years (1989/1990-1994/1995). Results of the JEVIN trial. J Diabetes Complic 2006; 20:273-279.
11. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-342. (Pubitemid 38101606)
12. Aguilar-Salinas CA, Velazquez Monroy O, Gomez-Perez FJ, Gonzalez Chavez A, Esqueda AL, Molina Cuevas V, et al. Characteristics of patients with type 2 diabetes in Mexico: results from a large population-based nationwide survey. Diabetes Care 2003; 26:2021-2026.
13. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006; 29:531-537.
14. Andros V. Uncontrolled blood pressure in a treated, high-risk managed care population. Am J Manag Care 2005; 11:S215-219.
15. Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis 2005; 46:1080-1087. (Pubitemid 41690234)
16. James P, Tan HH, MacAlpine R, Brennan G, Emslie-Smith A, Morris AD. Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study. Diabet Med 2004; 21:1108-1112.
17. Mehuys E, De Bolle L, Van Bortel L, Annemans L, Van Tongeien I, Remon JP, et al. Medication use and disease management of type 2 diabetes in Belgium. Pharm World Sci 2008; 30:51-56.
18. Passa P. Diabetes trends in Europe. Diabetes Metab Res Rev 2002; 18 (Suppl 3):S3-S8.
19. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444. (Pubitemid 23046633)
20. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ 1998; 317:720-726.
21. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253-259.
22. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/ beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project Diabetes Care 2001; 24:2091-2096. (Pubitemid 33716527)
23. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869. (Pubitemid 34940825)
24. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 ; 345:851-860.
25. Campese VM, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int 2007; 71:1215-1222.
26. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30:487-496. (Pubitemid 40070350)
27. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010. (Pubitemid 34286537)
28. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, prediabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Fur Heart J 2007; 28:88-136.
29. Koskinen S, Aromaa A. Health and functional capacity in Finland. Baseline results of the Health 2000 Health Examination Survey. Helsinki: National Public Health Institute. http://wwwktlfi/terveys2000/julkaisutbaselinepdf2004.
30. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289:2363-2369.
31. Efficacy of atenolol and Captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713-720.
32. Lindholm LH, Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18:1671-1675. (Pubitemid 30819656)
33. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41:431-436. (Pubitemid 36314612)
34. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of Perindopril and Indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840. (Pubitemid 47362321)
35. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding Perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
36. Ruggenenti P, Perna A, Ganeva M, Ene-lordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006; 17:3472-3481.
37. [Treatment of hypertension] updated version 2005 http://www. terveysportti.fi/pls/kh/kaypahoito?suositus=hoi04010 Duodecim 2002; 118:110-126.
38. Johnson ML, Singh H. Patterns of antihypertensive therapy among patients with diabetes. J Gen Intern Med 2005; 20:842-846.
39. Andros V, Egger A, Dua U. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. J Manag Care Pharm 2006; 12:303-309.
40. Chiang CW, Chen CY, Chiu HF, Wu HL, Yang CY. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 2007; 16:412-421.
41. Mainous AG 3rd, Diaz VA, Saxena S, Baker R, Everett CJ, Koopman RJ, et al. Diabetes management in the USA and England: comparative analysis of national surveys. J R Soc Med 2006; 99:463-469.
42. Safar ME, Boudier HS. Vascular development, pulse pressure and the mechanisms of hypertension. Hypertension 2005; 46:205-209.
43. Os I, Gudmundsdottir H, Kjeldsen SE, Oparil S. Treatment of isolated systolic hypertension in diabetes mellitus type 2. Diabetes Obes Metab 2006; 8:381-387.
44. Ogedegbe G. Barriers to optimal hypertension control. J Clin Hypertens (Greenwich) 2008; 10:644-646.